Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Cipla Ltd ( (IN:CIPLA) ).
Cipla Ltd has announced that its board has approved the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026, supported by an unmodified opinion from its statutory auditors. The company has also confirmed that the related documents, including the auditor’s reports and CFO declaration, will be made available on its investor website section.
The board has recommended a final dividend of INR 13 per equity share for the financial year ended 31 March 2026, with the dividend to be paid within 30 days of shareholder approval at the upcoming annual general meeting. For determining eligible shareholders, the company has set 5 June 2026 as the record date, signaling continued returns to investors alongside the completion of its annual financial reporting cycle.
More about Cipla Ltd
Cipla Ltd is a Mumbai-headquartered pharmaceutical company engaged in the development, manufacturing, and marketing of generic and branded medicines. It operates in India and globally with a focus on respiratory, cardiovascular, anti-infective, and other therapeutic segments, supplying both regulated and emerging markets.
Average Trading Volume: 104,364
Technical Sentiment Signal: Hold
Current Market Cap: 1043.7B INR
See more insights into CIPLA stock on TipRanks’ Stock Analysis page.